Brief: Biogen Provides Regulatory Update On High Dose Regimen Of Nusinersen
23/09/2025 23:14
Sept 23 (Reuters) - Biogen Inc BIIB.O: BIOGEN PROVIDES REGULATORY UPDATE ON HIGH DOSE REGIMEN OF NUSINERSEN BIOGEN INC - FDA REQUESTS UPDATE TO CMC MODULE IN BIOGEN'S SNDA BIOGEN INC - CRL DID NOT CITE DEFICIENCIES IN CLINICAL DATA FOR HIGH DOSE REGIMEN BIOGEN INC - TO RESUBMIT APPLICATION PROMPTLY Source text: ID:nGNX3XKGR4 Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study